Announcements

Class of ’61 Awards Presented to Drs. Fan and Guo
The leadership of Yale Cancer Center has selected Rong Fan, PhD, Professor of Biomedical Engineering and of Pathology, and Shangqin Guo, PhD, Associate Professor of Cell Biology, as the recipients of the Class of ’61 Cancer Research Awards for 2021. Both Dr. Fan and Dr. Guo are members of the Yale Stem Cell Center. The annual awards recognize significant accomplishments in cancer research at Yale Cancer Center by young members of the faculty, coupled with the expectation for future outstanding contributions to our understanding of the causes and cures for cancer.

“Dr. Fan and Dr. Guo are exceptional candidates for this important award,” said Daniel DiMaio, MD, PhD, Deputy Director of Yale Cancer Center and Waldemar Von Zedtwitz Professor of Genetics and Professor of Molecular Biophysics and Biochemistry and of Therapeutic Radiology, who helped lead the selection process, along with Mark Lemmon, PhD, Associate Cancer Center Director for Basic Science, Co-Director of the Yale Cancer Biology Institute, and Professor of Pharmacology. “These two outstanding scientists are rising stars in their fields and are already making a significant impact in cancer research.”

Dr. Fan is internationally recognized for his work in developing novel single-cell and spatial omics technologies and applying them to cancer research, including hematologic malignancy and immunology. His highly innovative research at Yale has made significant contributions to biomedical science, most recently identifying a new way to look at gene expression at the single-cell level.

Dr. Guo’s areas of expertise include myeloid leukemia, myeloid biology, hematopoietic stem cells, and regenerative medicine. Her scientific contributions have included a better understanding of mechanisms of malignant myeloid transformation, hematopoietic stem cell pluripotency, reprogramming, and lineage (myeloid) commitment, and cell cycle regulation of normal and malignant hematopoiesis.

News Center

Letter: Westerly Hospital a blessing for our community

Yale Cancer Center Study Demonstrates
The Class of ’61 Cancer Research Awards are supported through the Yale Class of 1961 Cancer Center Endowment, which was established in 2016 by the Yale College class. The endowment has honored one or more Yale Cancer Center faculty members each year since its inception with a grant to support their highly promising cancer research.

ACS Funds New Diversity in Cancer Research Program
The American Cancer Society has awarded Yale Cancer Center new supplemental funding to support a Diversity in Research Internship Program led by Joseph Contessa, MD, PhD, Professor of Therapeutic Radiology and Pharmacology and Co-Leader of the Yale Cancer Center Radiobiology and Radiotherapy Research Program, and Faye Rogers, PhD, Associate Professor of Therapeutic Radiology and Associate Director of the Yale MD-PhD Program. The new program will provide mentorship and a cancer-focused training experience for undergraduate students with a science major. Launching this summer, it will capitalize on the depth of basic, translational, and clinical cancer research at Yale Cancer Center to expand the Center’s commitment to advancing diversity in the biomedical workforce. Seasoned PhD and MD-PhD mentors will provide a supportive community for rigorous training and instruction in the fundamental biological principles in cancer research.

The American Cancer Society Diversity in Cancer Research (ACS-DICR) Program will be a 10-week, research-based, summer program focused on hands-on training in techniques relevant to cancer research, formalized educational opportunities with YCC researchers, and an introduction to Yale’s diverse and supportive community for cancer research. The goal of the program is to ignite a passion for cancer research and provide the selected undergraduates with insights into the field of cancer biology.

Notables

David Braun, MD, PhD, Assistant Professor of Medicine (Medical Oncology), has been selected as the recipient of the Spatial Multimomics Grant Award-CODEX from Akoya Biosciences to support his lab’s research to understand what features of the tumor-immune microenvironment impact response or resistance to current immunotherapy for kidney cancer. The team will use the funding to complete spatial characterization of already obtained pre-treatment tumor tissue and integrate it with their droplet-based scRNA-seq dataset to understand how cell-cell interactions and cellular “neighborhoods” in the microenvironment contribute to response and resistance.

Nikhil Joshi, PhD, Assistant Professor of Immunobiology and a member of Yale Cancer Center’s Cancer Immunology Research Program, has been recognized by The Mark Foundation for Cancer Research with their 2022 Emerging Leader Award. The award will support Dr. Joshi’s research into how T Cell immunosurveillance restricts progression of developing tumors.
Research Program welcomes Harry Sanchez, MD, Assistant Professor of Pathology and Director of the Yale Autopsy Service. Dr. Sanchez is currently developing the Yale Tissue Donation Program. The program will provide the opportunity for patients with late-stage cancer to consent to donate tissue for research post-mortem and concomitantly create the opportunity for YCC member access to “warm autopsy” tumor tissue from recently deceased individuals. With the appropriate partnerships with YCC members, this program, led by Dr. Sanchez, is likely to support new dimensions in basic and translational YCC research, including the interplay between systemic factors (e.g., metabolism and immune response) and tumor fitness and cellular phenotypes.

Diversity, Equity, and Inclusion

Picture a Professional: Rethinking Expectations of Medical Professionalism Through the Lens of Diversity, Equity, and Inclusion

This editorial in the *Journal of Clinical Oncology* by Abby Rosenberg, MD, MS, MA, Reshma Jagsi, MD, DPhil, and Jonathan M. Marron, MD, MPH, addresses ways in which the concept of “professionalism” is shaped by implicit biases. The authors argue that at a time when half of medical students are women and half identify as non-White, the absence of diverse and inclusive leadership in our field jeopardizes our ability to develop the diverse cancer workforce our patients deserve. They review ways in which traits associated with White male culture are seen to typify scientists and physicians by children surveyed even in the mid-2010’s, and argue that it is time to value diversity (difference) over fit (sameness). Please follow this link to read their compelling argument.

Learn More

Cindy Crusto, PhD, Appointed Associate Dean for Gender Equity and Director of the Office for Women in Medicine and Science at YSM

Cindy Crusto, PhD, Professor of Psychiatry, has been appointed Associate Dean for Gender Equity and Director of the Office for Women in Medicine and Science at Yale School of Medicine. Dr. Crusto will work along with Darin A. Latimore, MD, Deputy Dean of Diversity and Chief Diversity Officer, to fulfill the goals outlined in the YSM Diversity Strategic Plan, including increasing mentorship and networking opportunities for women faculty, sponsoring women for leadership positions, and promoting policies and procedures that benefit women faculty.

Employee Profile: Ruth Chapman

There is a rainbow of origami cranes in our healing garden on the 7th floor of Smilow Cancer Hospital! Many hands created this display of over 1500 paper cranes and we’re still collecting and adding more. Thank you to our Creative Expression Coordinator, Dana Brewer, and our Integrative Medicine team for their hard work on this festive and joyful display for our patients, families, and staff!
In her role as a Patient Financial Access Facilitator for just over a year now, Ruth Chapman said she learns something new every day; however, she is no stranger to the field of patient care. For over 13 years, 12 of them at Charlotte Hungerford Hospital in Torrington, Ruth worked as a Patient Care Technician and then went back to school and spent five years in Medical Coding, but realized she missed the daily patient interactions. She now works at the Smilow Cancer Hospital Care Centers in Torrington and Waterbury where she is responsible for all of the functions and processes involved with checking patients in and out, scheduling follow-ups and treatments, and sending outpatient referrals.

Ruth is there to greet patients when they arrive, and although she sees a lot of familiar faces, there are often new patients arriving as well. Ruth and her co-workers are the first people they see, and understandably they are often anxious upon arrival. “By far the best part of my job is the patients and families and the people that I work with. They are all amazing warriors and co-workers,” said Ruth.

As part of her role, Ruth also triages calls and alerts a patient’s doctor or nurse of any urgent needs or concerns. She is responsible for checking insurance and making sure the correct documents are signed so that patients get the coverage they need. If they have difficulty affording care, or do not have insurance, she then refers them to services that can help and answers any questions.

Andreina Boebel, PFAS Supervisor for the Smilow Cancer Hospital Care Centers in Derby, Waterbury, and Torrington commented, “Ruth is a tremendous addition to the team. She is always willing to help wherever she is needed and does so with a smile. The team and I are thankful to have her.”

Recent Publications

Phase 1 Study Of Anti-CD47 Monoclonal Antibody CC-90002 in Patients with Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
Annals of Hematology, Online ahead of print.
Read More

A Randomized Phase 2 Trial of Azacitidine ± Durvalumab as First-line Therapy for AML
Annals of Hematology, Online ahead of print.
Read More

After losing her husband to cancer 13 years ago, Arlene Mingione felt compelled to volunteer and started on an inpatient unit at Smilow Cancer Hospital while she returned to school for nursing. Now, she works to support patients at our Smilow Cancer Hospital Care Center in Guilford while working to earn her MSN. On a day-to-day basis, Arlene provides education and coordinates care for patients receiving oral chemotherapy, while also assisting with symptom management and transition of care, all by phone and EPIC communications.

“A much of my day is spent at my computer, in what I lovingly call my 'She-shed,' and although I miss the eye to eye and soul to soul connection with patients, I have found joy in helping my patients by ensuring they have what they need, especially complex patients who are very sick and may need help navigating care,” said Arlene. Every day brings new challenges, yet Arlene is ready to meet them as an advocate for her patients.

Dr. Elan Gorshein commented, “Arlene is arguably one of the hardest working, thorough, and diligent colleagues I have ever worked with. She consistently goes above and beyond for patient care.”

Meet This Week's Volunteer

Arlene Mingione, RN, BSN, MA,旅行者和注册护士，为患者和家庭提供支持和协调护理服务。她对患者的关心和对护理的热爱使她在护理领域中脱颖而出。
Therapy for Higher-Risk Myelodysplastic Syndromes
*Blood Advances*, Online ahead of print.
Read More

Cohen O, Brauer PR, Judson BL, Burtness BA, Earles J, Mehra S.
Guideline - Adherence in Advanced Stage Head and Neck Cancer is Associated with Improved Survival - a National Study
*Oral Oncology*, Online ahead of print.
Read More

Newly Identified Chemotherapy-Induced Peripheral Neuropathy In A Childhood Cancer Survivorship Clinic
*Pediatric Blood and Cancer*, Online ahead of print.
Read More

Somatic Mutation of BAP1 Can Lead to Expression Loss in Non-Small Cell Lung Carcinoma: Next Generation Sequencing and IHC Analysis in A Large Single Institute Cohort
Read More

Al-Jobory YM, Pan Z, Manes RP, Omay SB, Ikuta I.
Sinonasal Glomangiopericytoma: Review of Imaging Appearance and Clinical Management Update for a Rare Sinonasal Neoplasm
Read More

Correction to: The Integrated Multiomic Diagnosis Of Sporadic Meningiomas: A Review Of Its Clinical Implications
*Journal of Neuro-Oncology*, Online ahead of print.
Read More

MAL2 mediates the formation of stable HER2 signaling complexes within lipid raft-rich membrane protrusions in breast cancer cells
*Cell Reports*, 37(13):110160.
Read More

Granulocyte Colony-Stimulating Factor is Safe and Well Tolerated following Allogeneic Transplantation in Patients with Sickle Cell Disease
*Transplantation and Cellular Therapy*, Online ahead of print.
Read More

Jacobs JW, Guarente J, Hendrickson JE, Tormey CA, Bar N.

Read More
Autologous Hematopoietic Stem Cell Product Contaminated With Salmonella Due To Occult Salmonellosis In An Asymptomatic Donor
Journal of Clinical Apherisis, Online ahead of print.
Read More

Blank CU, Wong DJ, Ho TH, Bauer TM, Lee CB, Bene-Tchaleu F, Zhu J, Zhang X, Cha E, Szoln M.
Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors
Current Oncology, 28(6):5466-5479.
Read More

Clinical Decision Rule For Obtaining Peripheral Blood Cultures In Febrile Oncology Patients
Pediatric Blood & Cancer, Online ahead of print.
Read More

Monsrud AL, Avadhani V, Mosunjac MB, Flowers L, Krishnamurti U.
Programmed Death Ligand-1 Expression Is Associated With Poorer Survival in Anal Squamous Cell Carcinoma
Archives of Pathology & Laboratory Medicine, Online ahead of print.
Read More

Jairam V, Soulos PR, Gross CP, Yu JB, Park HS, Decker RH.
A reply to "Randomized controlled clinical trial is needed for toxicity of IMRT VS 3D-CRT in PORT for LA-NSCLC"
Lung Cancer, Online ahead of print.
Read More

The Breast Cancer Weight Loss trial (Alliance A011401): A Description And Evidence For The Lifestyle Intervention
Read More

A Humanized Mouse Model Of Chronic COVID-19
Nature Biotechnology, Online ahead of print.
Read More

Guo X, Xu L, Velazquez H, Chen TM, Williams R, Heller D, Burtness B, Safirstein R, Desir G.
Kidney-Targeted Renalase Agonist Prevents Cisplatin-Induced Chronic Kidney Disease by Inhibiting Regulated Necrosis and Inflammation
Journal of the American Society of Nephrology, Online ahead of print.
Read More

Our medical oncology outpatient teams from NP8 in New Haven and at our Smilow Cancer Hospital Care Center in North Haven celebrated the holiday season together by wearing festive sweaters, planning a gift exchange, and generously collecting Stop & Shop gift cards to distribute to some of their patients needing a little assistance over the holiday season. We know how hard all of our healthcare teams are working at Smilow Cancer Hospital and in our Care Centers, and love sharing their smiling photos with you all!

Brianna Gallant, BSN, RN, has been an Assistant Patient Services Manager at Smilow Cancer Hospital for a little over three years and the passion she has for the unit, the nurses, and the patients that she supports is evident every day. Brianna enjoys working with the team and being able to assist and encourage them in any way she can. Sandy Morgan, Patient Services Manager on NP7 said of her nomination, “Brianna is an amazing resource to all the staff on NP7. No matter what she is involved in, if someone needs help, she is the first one to volunteer.”

Read More

Smilow Stars
Thank you, Brianna Gallant!


Funding and Award Opportunities

**Bladder Cancer Research Innovation Awards**
This award supports experienced investigators with exceptionally novel and creative projects designed to produce significant advances in our understanding of the management of bladder cancer. The proposed research may be basic, translational, clinical or epidemiological and must have direct applicability and relevance to bladder cancer. Applications must include innovative approaches and new ideas to be eligible for funding.

**Application Deadline:** January 12, 2022

Read More

**Susan D. Flynn Oncology Nursing Fellowship at Smilow Cancer Hospital**
The Susan D. Flynn Oncology Nursing Fellowship Program at Smilow Cancer Hospital is intended to help stimulate the career interest and foster the professional development of future oncology nurses. Since 2014, we have awarded fellowships to numerous exceptional nurses from across the United States. Past fellows have landed positions at prestigious hospitals, including the Memorial Sloan-Kettering Cancer Center, the National Institutes of Health, and Boston Children's Hospital.

Read More

We are incredibly grateful to Dr. Robert Garofalo for his insight and leadership as Associate Director for Research Affairs for Yale Cancer Center since 2015 and wish him well as he begins his retirement next month. He and his team have helped to support the exponential growth of our research enterprise. Prior to joining Yale Cancer Center, Dr. Garofalo served as Chief of Endocrinology, Metabolism, Nutrition and Reproductive Sciences Integrated Review Group at the Center for Scientific Review at the National Institutes of Health. We appreciate his assistance and mentorship and wish him all the best!

Following research led by Dr. Jane Kanowitz and Paula Pike at the Smilow Cancer Hospital Care Center in North Haven, Smilow Cancer Hospital and its Network sites are implementing use of a chemotherapy toxicity calculator for patients over the age of 70. Data showed that the unbiased tool predicts risk of toxicity, the risk of hospitalization, and the need to either lower the dose of chemotherapy or change the treatment plan; it also neutralizes unconscious biases that
the professional development of future oncology nurses. Since 2014, Greenwich Hospital has been home to the Fellowship, but this year the program will be expanded to Smilow Cancer Hospital in New Haven as well. Six undergraduate nursing students enrolled in a BSN program who have just completed their junior year will be chosen for an immersive 8-week experience in oncology nursing; two at Greenwich Hospital and four in New Haven.

The fellowship will enhance the student’s core clinical education through direct observation and exposure to oncology nursing care. Through this experience, students will learn about the various oncology nursing roles and responsibilities and discover possible career opportunities.

**Application Deadline:** January 14, 2022. Applications should be sent to: kristina.capretti@greenwichhospital.org

**http://sdfondp.com/**

The Jackson Laboratory – Yale Cancer Center Joint Pilot Project Grant: Deciphering the Tumor Microenvironment Using Advanced Imaging and Analysis

The pilot funding will support innovative cancer research on the topic of “Deciphering the Tumor Microenvironment Using Advanced Imaging and Analysis.” Proposals may be focused on spatial data analysis, technology investigation, or hypothesis-based research making innovative use of advanced imaging techniques.

**Proposals are due by:** January 14, 2022. Email your application to: jaxccadmin@jax.org

**Read More**

BMSF Diversity in Clinical Trials Career Development Program

The intent of this program is to increase diversity in clinical trials. The initiative is comprised of a Career Development Program for early-stage clinical investigators and a Clinical Investigator Pipeline Program (BMSF CIPP) for rising second-year medical students.

**Application Deadline:** January 14, 2022

**Read More**

ASCO Medical Student Rotation for Underrepresented Populations

Provides financial support for U.S. medical students from populations underrepresented in medicine and who are interested in oncology as a career to experience a minimum 4-week clinical or clinical research rotation.

**Application Deadline:** January 25, 2022

**Read More**

ASCO Diversity Mentoring Program

Designed to encourage U.S. based medical students and residents who are underrepresented in medicine to pursue rewarding careers in oncology by pairing with a mentor.

**Application Deadline:** January 25, 2022

**Read More**

BMSF Clinical Investigator Pipeline Program

This Program was established to build the pipeline of community oriented clinical trialists of diverse backgrounds who are committed to increasing diversity, equity and inclusion in clinical trials. This will be a 6-week summer externship program for 250 underrepresented medical students, and with hands-on community-oriented clinical trial experience in underserved communities will also neutralize unconscious biases that can affect treatment.

**Read More**

When the National Cancer Act became law 50 years ago today in 1971, it launched a nationally coordinated approach to cancer research. This landmark legislation pushed us to find new ways to advance clinical trials that led to revolutionary cancer treatments, immunotherapies, targeted therapies, and advanced tumor imaging, and ultimately, has led to better quality and longevity of life for our patients.

Today we recognize its progress, honor the significance of Yale Cancer Center's National Cancer Institute's Comprehensive Cancer Center designation, and promise to continue to push for advances and progress in the years to come.

**Read More**

Our nursing team at the Smilow Cancer Hospital Care Center in Torrington are in the holiday spirit today and spreading cheer to our patients and families!
with hands-on community-oriented clinical trial experience in underserved communities.

**Application Deadline:** January 28th, 2022

**Read More**

**AACR Gertrude B. Elion Cancer Research Award**
Applications are now being accepted for this one-year, $75,000 grant with generous support from GlaxoSmithKline. This opportunity represents a joint effort to encourage and support tenure-eligible junior faculty. The research proposed for funding must focus on cancer etiology, diagnosis, treatment, or prevention and may be basic, translational, or clinical in nature.

**Application Deadline:** January 31, 2022

**Read More**

**Leslie Warner Postdoctoral Fellowships for Cancer Research**
The Fellowships will support early-stage promising trainees that are conducting innovative basic, translational, clinical, or population-based cancer research with a Yale Cancer Center member. Relevance of proposed research to our catchment area priorities is also encouraged. Candidates may have up to one year of postdoctoral experience from the time of application.

**Internal Deadline:** February 1, 2022

**Read More**

**Leukemia Research Foundation Grant**
The application process for the 2022-2023 funding cycle has begun! Grants of up to $100K are available to new investigators -- researchers within seven years of their first independent faculty-level position. Research projects must focus on a blood cancer (leukemia, lymphoma, myeloma, or MDS).

**Letter of Intent Due:** February 4, 2022

**Read More**

**Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R01, R21)**
The purpose of this FOA is to support basic research that elucidates mechanisms by which the human microbiome inhibits or enhances anti-tumor immune responses, and to identify potential novel molecular targets for cancer prevention strategies.

**Application Deadline:** February 5, 2022

**Read More**

**Pediatric Oncology Student Training (POST) Program**
As part of the Alex’s Lemonade Stand Foundation (ALSF), the POST Program is designed for undergraduate, graduate, and medical students who have an interest in pediatric oncology research and would like to experience the field firsthand. Students train with a pediatric oncology research mentor. Students may join a research project underway in a mentor’s lab or begin an original investigation with the mentor.

**Application Deadline:** February 21, 2022

**Read More**

**Early K99/R00 Funding Opportunity Announcements**
The NCI just reissued “early K99/R00" - NCI Pathway to Independence Award for Outstanding Early-Stage Postdoctoral Researchers FOAs that might be of interest to some postdoctoral fellows.

- NCI Pathway to Independence Award for Outstanding Early-Stage Postdoctoral Researchers (R00)

**Read More**

---

50 years ago today, the National Cancer Act was signed into law by President Nixon. Yale Cancer Center’s Vincent T. DeVita, Jr., MD, is shown reminiscing with the President over the importance of the Cancer Act several years later. Today, Dr. DeVita comments, “The signing of the National Cancer Act 50 years ago set into motion a series of events that have ultimately led to life-saving cancer treatments, immunotherapies, targeted therapies, and advanced tumor imaging. I have always said that to dedicate yourself to helping people survive, especially to survive this disease, you have to be an eternal optimist. There is now something we can do to treat virtually anyone with cancer, and I truly believe the best is yet to come. This one Act, along with dedicated researchers and courageous patients, has made this a reality, and over time I have only grown more optimistic for the future.”

---

90% of patients with cancer experience cancer-related fatigue during their treatment and 30% of cancer survivors suffer from fatigue years after treatment. Tara Sanft, MD, Chief Patient Experience Officer at Smilow Cancer Hospital, reminds our
NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed)

NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required)

NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)

Application Deadlines: February 28, 2022
Read More

NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00)
The purpose of this award is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions.
Application Deadline: February 28, 2022
Read More

NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)
This FOA is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind.
Application Deadline: February 28, 2022
Read More

DeLuca Career Development Award 2022
The purpose of this career development award is to provide early career clinical or laboratory-based investigators in Hematology, the opportunity to focus on research to advance patient care, therapies, and outcomes and with the ultimate goal to achieve independent support for their research from a national agency. For further information contact Richard.Carr@yale.edu
Letter of Intent Due: March 1, 2022
Read More

American Cancer Society - Institutional Research Grant Pilot Awards
The purpose of this grant is to provide seed money (up to $30,000 total for one year) for the initiation of promising new projects or novel ideas by Yale Assistant Professors so that they can obtain preliminary results to enable them to compete successfully for national cancer research grants. Investigators who have obtained a competitive national research grant are not eligible for support through this mechanism, unless such a grant is primarily for faculty salary. Recipients of previous ACS-IRG Awards, research grants from National Foundations or the tobacco industry, and established

Smilow Cancer Hospital, reminds our patients to reach out to their care team if they need support during this holiday season.

Pat Unan and Linda Johnson, organizers of the summer Boobstock music festival held annually in Deep River, CT, presented a check for over $6,000 to be directed to assistance for patients with breast cancer at the Cingari Family Boutique at Smilow Cancer Hospital. Thank you Pat and Linda for all your efforts with this unique event!

Our Smilow Cancer Hospital Care Center in North Haven got into the holiday spirit by decorating all the clinic windows!
grants from National Foundations or the tobacco industry, and established investigators, are also ineligible.

**Letter of Intent Due:** March 1, 2022

**The Mark Foundation Endeavor Awards**

These awards support collaborative research projects that bring together investigators with diverse areas of expertise to tackle challenges in the prevention, diagnosis, and treatment of cancer. These grants are awarded to teams of three or more investigators to generate and integrate data from diverse lines of research and transform those insights into advances for cancer patients that could not be achieved by individual efforts.

**Letter of Intent Due:** March 1, 2022

**Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61)**

This FOA solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses.

**Application Deadline:** April 22, 2022

**Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33)**

This FOA solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous validation to encourage adoption by the research community.

**Application Deadline:** April 22, 2022

**@NCCN released new #COVID19 vaccination guidelines to protect people w/cancer based on the latest FDA approvals & surging infections, including expertise from @SmilowCancer physicians @KerinAdelsonMD, @MichaelEHurwitz & Dr. Thomas Prebet.**

**A new study led by @YaleENT and @BarbaraBurtness reports @NCCN guideline adherence in advanced #headandneckcancer improves survival and recommends increased awareness.**

**Thanks to the inspiring leadership of Drs. Anna Kress & Benjamin Lu @Benjamin_Y_Lu, our @YaleHemOnc Fellowship Program has Diversity, Equity & Inclusion #DEI curriculum integrated into the didactic component of training.**

**A review and meta-analysis led by @JamesFarrellGI & @AnkitChhoda reported in @AGA_Gastro showed a sizable proportion of late-stage #pancreaticcancers detected during surveillance in high-risk patients.**

**In an editorial in @JCO_ASCO, Dr. Harriet Kluger discusses the impact of the CheckMate-067 clinical trial for the treatment of patients with advanced #melanoma.**

**Read all about it! @AnneChiangMD, @DrRoyHerbstYale & members of the Center for Thoracic Cancers have co-edited and published a new book, "Lung...**
Congratulations to Dr. Nancy Ruddle named a 2022 Distinguished Fellow of the American Association of Immunologists @ImmunologyAAI in recognition of her excellence in research and leadership in the field of #immunology.

The National Cancer Act became law 50 years ago & launched a coordinated approach to cancer research. We recognize its progress, honor the significance of Yale Cancer Center's the NCI Comprehensive Cancer Center designation & promise to push for progress.

50 years ago, the National Cancer Act was signed. @DeVitaDoctor is shown reminiscing important moments in his presidency with President Nixon, including the Act. Today, Dr. DeVita comments on its importance, and the promise it holds for future research.

Congratulations to SanjayAnejaMD recipient of the 2022 William O. Seery Clinical Investigator Grant from the Patterson Trust Foundation to study deep learning derived imaging biomarkers for #lungcancer.

@maryam_lustberg & colleagues review recent research to help improve sexual desire in postmenopausal women with breast or gynecologic cancers and find a multidisciplinary approach is likely key.

We are proud to announce @RongFan8 and Dr. Shangqin Guo @GuoLabatYale as recipients of the 2021 Class of '61 Cancer Research Awards in recognition of their accomplishments in #cancerresearch.

We are proud to announce four @YaleCancer members have been appointed to endowed professorships this month! Congratulations to Ranjit Bindra @ranjitbindra, Stephanie Halene @Halene_lab, Suchitra Krishnan-Sarin @KrishnanSarin, and David Rimm @RimmPathology.
@cpgYALE calls for a 'National Cancer Plan 2.0' with four priorities: Prioritizing prevention, Revamping drug pricing, Addressing disparities & Rebalancing our approach to clinical cancer research.

Calendar

Yale Cancer Answers
January 9; 7:30 PM
NPR
Liver Toxic Medications and Liver Cancer Risk
Amy Justice, MD, PhD & Vincent Lo Re III, MD, MSCE
Learn More

Radiobiology and Genome Integrity Research Program
January 10; 11:00 AM
Mutant Cells and Clones and Genomic Dosimeters of Past Sun Exposure
Douglas Brash, PhD & Vijay Menon
Learn More

Yale RNA Club
January 11; 8:45 AM
Learn More

Yale Cancer Center Grand Rounds
January 11; 12:00 PM
A NET Gain: Establishing the Yale Neuroendocrine Tumor Program and Merkel Cell Carcinoma: Past, Present and Future Directives
Pamela Kunz, MD and Kelly Olino, MD, FACS
Learn More

Immune Development Interest Group Seminar Series
January 12; 4:00 PM
Ofer Levy, MD, PhD
Learn More

Yale Cancer Center Seminar
January 12; 5:00 PM
Women’s Health in Hematology
Layla Van Doren, MD
Learn More

2021-2022 Immunobiology Seminar Series
X-Chromosome Inactivation in the Immune System: Understanding the Genetic Contributions towards Female-biased Autoimmunity
Montserrat Anguera, PhD
Learn More

Pharmacology Seminar Series
January 13; 12:30 PM
Proteomes in 3D: Structural Barcodes to Probe Protein Functional Alterations
Dr. Paola Picotti
Learn More

Pathology Grand Rounds
January 13; 12:30 PM
What Makes the Lymphoid Proliferation Associated with Infective Agents Unique?
Kikkeri Naresh, MBBS, MD
Learn More

Center for GI Cancers Weekly Seminar
January 13; 4:15 PM
GI Grant Opportunities and GI Biorepository Update
Pamela Kunz, MD | Mandar Deepak Muzumdar, MD | Edward Kaftan, PhD | John Kunstman, MD, MHS, FACS
Learn More

Yale Cancer Answers
January 16; 7:30 PM
NPR
Decreasing Toxicities of Radiation Therapy for Breast Cancer Patients
Meena S. Moran, MD
Learn More

Yale Cancer Center Grand Rounds
January 18; 12:00 PM
Dr. Kathryn Miller-Jensen and Clare Flannery, MD
Learn More

Yale Cancer Biology Institute/Center of Molecular and Cellular Oncology Seminar
January 18; 1:00 PM
Mechanisms of Malignant Transformation of the Immune System
Ari Melnick, MD
Learn More
Yale Head and Neck SPORE’s Monthly Meeting
January 18; 5:00 PM
Learn More

Cancer Genetics and Prevention Seminar
January 19; 6:00 PM
Learn More

Center for GI Cancers/Yale PaCC Seminar
January 20; 2:30 PM
Learn More

New-Onset Diabetes And The Early Detection Of Pancreatic Cancer
Suresh T. Chari, MD
Learn More

Share your news!
Please submit your recent publications, awards, and grant announcements to:

Renee Gaudette
Director, Public Affairs and Communications